These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1086 related items for PubMed ID: 25665143

  • 1. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P, Richter L, Saxinger W, Vasiljevic M, Stingl G.
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [Abstract] [Full Text] [Related]

  • 3. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

  • 4. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M, Galluzzo M, Bernardini N, Caldarola G, Persechino S, Cantoresi F, Egan CG, Potenza C, Peris K, Bianchi L.
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K, Burden AD, Eaton JN, Hawkins NS.
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN.
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [Abstract] [Full Text] [Related]

  • 7. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of biologic therapies in psoriasis vulgaris.
    Mala R, Fida M, Jorgaqi E, Vasili E.
    Dermatol Ther; 2019 Jul; 32(4):e12936. PubMed ID: 30983095
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
    Zhang Z, Schmitt J, Wozel G, Kirch W.
    Med Klin (Munich); 2009 Feb 15; 104(2):125-36. PubMed ID: 19242664
    [Abstract] [Full Text] [Related]

  • 12. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP, Lewis VJ, Finlay AY.
    Br J Dermatol; 2007 May 15; 156(5):945-50. PubMed ID: 17388922
    [Abstract] [Full Text] [Related]

  • 13. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug 15; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 14. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F, Carlsson KS, Schmitt-Egenolf M.
    Br J Dermatol; 2018 Jan 15; 178(1):245-252. PubMed ID: 28644904
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, Beylot-Barry M, Séneschal J, Dubertret L, Morand JJ, Dréno B, Bachelez H, Groupe Français de Recherche sur le Psoriasis.
    Br J Dermatol; 2012 Aug 15; 167(2):417-23. PubMed ID: 22413927
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 15; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 18. On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis.
    Puig L.
    J Clin Pharm Ther; 2015 Apr 15; 40(2):131-4. PubMed ID: 25627250
    [Abstract] [Full Text] [Related]

  • 19. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
    Tampouratzi E, Sfaelos K, Talaiporou K, Douvali Τ, Katsantonis J.
    Acta Dermatovenerol Croat; 2023 Aug 15; 31(1):48-50. PubMed ID: 37843093
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.